Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Fineline Cube Aug 5, 2026
Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Fineline Cube Aug 5, 2026
Company Deals R&D

Sequanta Technologies and Iomics Bio Collaborate on Multi-Omics Research

Fineline Cube Dec 12, 2022

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Iomics Biosciences...

Company Deals

Innoforce Partners with RNAimmune for mRNA Development and Production

Fineline Cube Dec 12, 2022

Hangzhou-based biopharma partner company Innoforce Pharmaceuticals Co., Ltd struck a partnership with RNAimmune, a spin-off...

Company Medical Device

NMPA Approves COVID-19 Antigen Detection Reagents from Four Companies

Fineline Cube Dec 12, 2022

The National Medical Products Administration (NMPA) announced the marketing approvals for COVID-19 antigen detection reagents...

Company Deals

Biozon Partners with Agilent Technologies to Boost ICP-MS in China Clinics

Fineline Cube Dec 12, 2022

Zhejiang-based third-party detection service company Biozon struck a partnership with US firm Agilent Technologies. The...

Company Drug

Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review

Fineline Cube Dec 12, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New...

Company Deals

Acotec Scientific and Boston Scientific Enter Acquisition and Collaboration Agreement

Fineline Cube Dec 12, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) and US major Boston Scientific Corporation (NYSE: BSX)...

Company Drug

Biogen’s Aducanumab Administered to Chinese Patient for First Time

Fineline Cube Dec 12, 2022

US major Biogen’s (NASDAQ: BIIB) Alzheimer’s disease (AD) therapy aducanumab has been administered to a...

Company Drug

Stemirna Therapeutics’ COVID-19 mRNA Vaccine Gets EUA in Laos

Fineline Cube Dec 12, 2022

Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use...

Company Deals Digital

Medbanks Set for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 12, 2022

Sipai Health Technology Co., Ltd, also known as Medbanks, is set to make an initial...

Company Drug

Fujian Cosunter Completes Enrollment for Phase I Study of GST-HG171

Fineline Cube Dec 12, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced the completion of the enrollment of...

Company Drug

Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022

Fineline Cube Dec 12, 2022

China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at...

Company Deals

Roche and Zhongshan Hospital Collaborate on Clinical Studies and Innovation Center

Fineline Cube Dec 12, 2022

Swiss giant Roche’s (SWX: ROG) China unit and Roche Diagnostics’ China unit entered into a...

Company Drug

ASH 2022: China Biotechs Showcase Latest Clinical Trial Results

Fineline Cube Dec 12, 2022

The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...

Company Deals R&D

Merck Partners with Tsinghua Shenzhen for Organoid 3D Printing System

Fineline Cube Dec 12, 2022

Germany giant Merck (NYSE: MRK) struck a three-year partnership with Tsinghua Shenzhen International Graduate School,...

Company Deals

Luye Pharma Group Hands Over Seroquel Distribution Rights to DCH Auriga in Singapore

Fineline Cube Dec 12, 2022

China-based Luye Pharma Group announced that it is handing Singapore distribution and marketing rights to...

Company Drug

RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers

Fineline Cube Dec 9, 2022

China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...

Company Drug

Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022

Fineline Cube Dec 9, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...

Policy / Regulatory

NMPA Extends Validation Period for COVID-19 Antigen Detection Reagents

Fineline Cube Dec 9, 2022

The National Medical Products Administration released a notification extending the validation period of approvals for...

Company Deals

Science Standard Medical Testing Raises Pre-Series A Funding

Fineline Cube Dec 9, 2022

Science Standard Medical Testing, a professional third-party testing institution based in Changzhou, reportedly raised “tens...

Company Deals

Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199

Fineline Cube Dec 9, 2022

Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...

Posts pagination

1 … 626 627 628 … 704

Recent updates

  • Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
  • Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline
  • Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication
  • Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance
  • Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Company

Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline

Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.